- Using stem cells to grow new hair
- Promising use of nanodiamonds in delivering cancer drug to kill cancer stem cells
- Does gestational diabetes affect the therapeutic potential of umbilical cord-derived stem cells?
- Stem cell transplantation shows potential for reducing disability in patients with MS
- Stem cells derived from amniotic tissues have immunosuppressive properties
- Bone stem cells shown to regenerate bone and cartilage in adult mice
- Bone stem cells shown to regenerate bones and cartilage in adult mice
- Hope for muscular dystrophy patients: Harnessing gene helps repair muscle damage
In a new study from Sanford-Burnham Medical Research Institute (Sanford-Burnham), researchers have used human pluripotent stem cells to generate new hair. The study represents the first step toward the development of a cell-based treatment for people with hair loss. In the United States alone, more than 40 million men and 21 million women are affected by hair loss. The research was published online in PLOS Oneyesterday.
A study led by the National University of Singapore (NUS) found that attaching chemotherapy drug Epirubicin to nanodiamonds effectively eliminates chemoresistant cancer stem cells. The findings were first published online in ACS Nano, the official journal of the American Chemical Society, in December 2014.
Multipotent cells isolated from the human umbilical cord, called mesenchymal stromal cells (hUC-MSCs) have shown promise for use in cell therapy to treat a variety of human diseases. However, intriguing new evidence shows that hUC-MSCs isolated from women with gestational diabetes demonstrate premature aging, poorer cell growth, and altered metabolic function, as reported in an article in Stem Cells and Development, a peer-reviewed journal fromMary Ann Liebert, Inc., publishers. The article is available free on the Stem Cells and Development website until February 17th, 2015.
Results from a preliminary study indicate that among patients with relapsing-remitting multiple sclerosis (MS), treatment with nonmyeloablative hematopoietic stem cell transplantation (low intensity stem cell transplantation) was associated with improvement in measures of disability and quality of life, according to a study in the January 20 issue of JAMA.
Stem cells derived from human amnion have for some time been considered promising for cell therapies because of their ease of access, ability to differentiate, and absence of ethical issues. Now, a Japanese research team has found that stem cells derived from human female amnion also have immunosuppressive activity and that the addition of antibodies to specific factors can enhance their immunosuppressive potential.
A stem cell capable of regenerating both bone and cartilage has been identified in bone marrow of mice. The discovery by researchers at Columbia University Medical Center (CUMC) is reported today in the online issue of the journal Cell.